Gina Eagle, MD
Insmed Incorporated
8
0
7
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Deniz Inal-Ince, PhD
Hacettepe University
Shared therapeutic areas:
Aslihan Cakmak, MSc
Hacettepe University
Shared therapeutic areas:
Sheila M. Innis, Dr.
University of British Columbia
Shared therapeutic areas:
Jae-Joon Yim, MD
Seoul National University Hospital
Shared therapeutic areas:
Shawn Aaron, MD
The Ottawa Hospital
Shared therapeutic areas:
Rémi Rabasa-Lhoret
Institut de Recherches Cliniques de Montreal
Shared therapeutic areas:
Mary Noseworthy, MD
Janeway Children's Health & Rebab. Centre, St. John's
Shared therapeutic areas:
Davide CAIMMI
University Hospital, Montpellier
Shared therapeutic areas:
Jacques-Edouard Marcotte, MD
CHU Ste-Justine, Montreal
Shared therapeutic areas:
Felix Ratjen, MD
The Hospital for Sick Children, Toronto
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
All 8 trials loaded